Latest Period
Q1 2026
Security Snapshot
Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT) Institutional Ownership
CUSIP: 03969K108
13F Institutional Holders and Ownership History from Q1 2020 to Q1 2026
Institutions Reporting
267
Shares (Excl. Options)
132,181,930
Price
$23.56
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / COMMON STOCK
- Symbol
- ARQT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 132,181,930
- Total 13F value
- $3,113,958,768
- Portfolio coverage rank
- 0%
- Share change
- +2,607,117
- Value change
- +$53,515,116
- Number of holders
- 267
- Shares outstanding
- 123,454,843
- SEC-reported price per share
- $21.69
- Insider filing price
- $21.69
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
3 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- ARQT - Arcutis Biotherapeutics, Inc. - COMMON STOCK is tracked under CUSIP 03969K108.
- 267 institutions reported positions in Q1 2026.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 280 to 267 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $3,744,475,286 to $3,113,958,768.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 267 institutions filings for Q1 2026.
Security key
03969K108
Latest holder period
Q1 2026
13F holders
267
13D/G owners
6
CIK / CUSIP context first
Open Q1 2026 holders
ARQT full holder history
Arcutis Biotherapeutics, Inc. SEC filings
Arcutis Biotherapeutics, Inc. company facts
Arcutis Biotherapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 03969K108:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
ARQT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Frazier Life Sciences VIII, L.P. | 7.5% | $130,399,321 | 8,943,712 | Patrick J. Heron | 18 Aug 2025 | |||
| Rubric Capital Management LP | 6.8% | $239,875,733 | 8,271,577 | Rubric Capital Management LP | 31 Dec 2025 | |||
| STATE STREET CORP | 5.1% | $151,864,272 | 6,296,197 | STATE STREET CORPORATION | 31 Mar 2026 | |||
| PRUDENTIAL FINANCIAL INC | 4.3% | -23% | $127,901,438 | -$42,866,378 | 5,302,713 | -25% | PRUDENTIAL FINANCIAL INC | 31 Mar 2026 |
| Polar Capital Holdings Plc | 4.2% | -24% | $75,147,145 | -$25,517,045 | 5,006,472 | -25% | Polar Capital Holdings Plc | 30 Jun 2025 |
| JENNISON ASSOCIATES LLC | 4% | -25% | $120,136,172 | -$42,866,932 | 4,980,770 | -26% | Jennison Associates LLC | 31 Mar 2026 |
As of 31 Mar 2026, 267 institutional investors reported holding 132,181,930 shares of Arcutis Biotherapeutics, Inc. - COMMON STOCK (ARQT). This represents 107% of the company’s total 123,454,843 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
81%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| SUVRETTA CAPITAL MANAGEMENT, LLC | 10% | 12,327,000 | +3% | 7.9% | $290,424,120 |
| Frazier Life Sciences Management, L.P. | 8% | 9,874,511 | 0% | 6% | $232,643,479 |
| BlackRock, Inc. | 7.5% | 9,200,411 | +1.1% | 0% | $216,761,686 |
| Rubric Capital Management LP | 6.7% | 8,271,577 | 0% | 2.4% | $194,878,354 |
| STATE STREET CORP | 5.1% | 6,296,197 | +15% | 0.01% | $148,338,401 |
| Polar Capital Holdings Plc | 4.6% | 5,666,940 | +2% | 0.58% | $133,513,106 |
| JENNISON ASSOCIATES LLC | 4% | 4,980,770 | -26% | 0.08% | $117,346,943 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.9% | 4,871,536 | 0% | 0% | $114,773,388 |
| GILDER GAGNON HOWE & CO LLC | 3.5% | 4,304,010 | -3.4% | 1.2% | $101,402,476 |
| MORGAN STANLEY | 3.4% | 4,218,930 | -2.8% | 0.01% | $99,397,993 |
| UBS Group AG | 2.7% | 3,329,224 | +2.6% | 0.01% | $78,436,518 |
| GEODE CAPITAL MANAGEMENT, LLC | 2.5% | 3,045,306 | +11% | 0% | $71,759,223 |
| D. E. Shaw & Co., Inc. | 2% | 2,496,222 | -7% | 0.05% | $58,810,990 |
| MARSHALL WACE, LLP | 2% | 2,431,778 | +435% | 0.06% | $57,292,689 |
| FRANKLIN RESOURCES INC | 1.9% | 2,297,943 | +21% | 0.01% | $54,139,548 |
| Driehaus Capital Management LLC | 1.8% | 2,226,029 | -13% | 0.39% | $52,445,243 |
| BANK OF AMERICA CORP /DE/ | 1.8% | 2,221,289 | +33% | 0% | $52,333,569 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 1.6% | 1,954,685 | 0% | 0% | $46,052,379 |
| JANUS HENDERSON GROUP PLC | 1.5% | 1,854,566 | +1.3% | 0.02% | $43,684,303 |
| GOLDMAN SACHS GROUP INC | 1.3% | 1,603,013 | +1.7% | 0% | $37,766,986 |
| AMERICAN CENTURY COMPANIES INC | 1.2% | 1,463,228 | -0.27% | 0.02% | $34,473,689 |
| OBERWEIS ASSET MANAGEMENT INC/ | 1.1% | 1,365,941 | +69% | 0.95% | $32,181,570 |
| Pivotal bioVenture Partners Investment Advisor LLC | 1.1% | 1,355,892 | -0.79% | 11% | $31,944,816 |
| Ensign Peak Advisors, Inc | 1% | 1,244,387 | -35% | 0.05% | $29,317,758 |
| Squarepoint Ops LLC | 0.89% | 1,103,490 | +142% | 0.06% | $25,998,224 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
25
Latest
Q1 2026
Rows shown
1-25 of 25
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 132,181,930 | $3,113,958,768 | +$53,515,116 | $23.56 | 267 |
| 2025 Q4 | 128,962,296 | $3,744,475,286 | +$103,845,955 | $29.04 | 280 |
| 2025 Q3 | 125,804,940 | $2,370,184,094 | -$12,772,142 | $18.85 | 235 |
| 2025 Q2 | 127,080,415 | $1,781,069,063 | +$21,637,125 | $14.02 | 228 |
| 2025 Q1 | 125,020,441 | $1,954,466,256 | -$63,284,061 | $15.64 | 239 |
| 2024 Q4 | 128,710,441 | $1,792,934,402 | +$13,789,213 | $13.93 | 206 |
| 2024 Q3 | 128,641,664 | $1,198,282,493 | +$15,921,001 | $9.30 | 187 |
| 2024 Q2 | 126,503,507 | $1,176,619,915 | +$9,242,287 | $9.30 | 184 |
| 2024 Q1 | 124,986,945 | $1,238,517,575 | +$285,414,998 | $9.91 | 166 |
| 2023 Q4 | 101,272,913 | $327,119,655 | +$79,248,549 | $3.23 | 130 |
| 2023 Q3 | 67,159,664 | $356,705,615 | -$26,597,323 | $5.31 | 131 |
| 2023 Q2 | 71,766,867 | $683,988,878 | -$5,745,956 | $9.53 | 135 |
| 2023 Q1 | 71,600,840 | $787,595,702 | +$44,255,428 | $11.00 | 141 |
| 2022 Q4 | 65,632,382 | $971,340,873 | +$87,400,990 | $14.80 | 138 |
| 2022 Q3 | 59,389,299 | $1,134,920,691 | +$194,978,652 | $19.11 | 138 |
| 2022 Q2 | 49,075,739 | $1,045,833,934 | +$17,642,019 | $21.31 | 112 |
| 2022 Q1 | 48,307,139 | $929,780,885 | -$136,426,148 | $19.26 | 106 |
| 2021 Q4 | 46,348,278 | $961,255,152 | -$1,852,441 | $20.74 | 89 |
| 2021 Q3 | 45,697,453 | $1,091,410,573 | +$4,816,184 | $23.89 | 103 |
| 2021 Q2 | 45,474,760 | $1,240,848,739 | -$38,040,013 | $27.29 | 100 |
| 2021 Q1 | 46,841,365 | $1,354,985,371 | +$170,660,745 | $28.93 | 93 |
| 2020 Q4 | 40,973,719 | $1,152,598,120 | +$138,537,380 | $28.13 | 78 |
| 2020 Q3 | 34,766,158 | $1,018,651,387 | +$28,894,471 | $29.30 | 62 |
| 2020 Q2 | 33,776,828 | $1,021,408,758 | +$33,104,690 | $30.24 | 55 |
| 2020 Q1 | 32,683,658 | $973,975,747 | +$973,295,747 | $29.80 | 49 |